Pfizer’s Waxman to Leave

Pfizer’s Waxman to Leave
Remains Outside Counsel Through Transition Period

NEW YORK--(BUSINESS WIRE)--Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel to Pfizer through a transition period.

Pfizer said David Reid, currently Senior Vice President and Managing Director, will assume Mr. Waxman’s responsibilities on an interim basis while the company conducts a search for a permanent successor.

“Allen and his team have been strong advocates for Pfizer, securing a number of important legal decisions that are significant for our business and our future,” said Jeff Kindler, Chairman and Chief Executive Officer. “Allen has provided valuable counsel not only on legal matters but on our overall business strategy and the issues facing Pfizer in its operating environment. He has made many contributions to our company. We thank him for those contributions and wish him well in his future endeavors.”

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.